RxDoctor Payments Data

Tamara Ivers, MD

Cardiovascular Disease · Grand Blanc, MINPI 1538691209

Payments from drug & device makers

$2,413in general payments, 2019–2025

Across 40 payments — averaging $60.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$567
  • Abiomed$534
  • Edwards Lifesciences$413
  • Medtronic$221
  • Boston Scientific$138
  • Medical Device Business Services, Inc.$137
  • plus $404 from 8 others

What the payments were for

  • Travel & lodging$362%
  • Food & beverage$1,98482%
  • Education$39216%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,413 in reported general payments places this provider in the 40th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$145,374
Medicare patients
684
Services billed
1,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$65,354
XareltoRivaroxaban16$14,771
Metoprolol Succinate100$1,975
Rosuvastatin Calcium49$1,216
Atorvastatin Calcium55$986
Losartan Potassium62$793
Spironolactone43$522
Ezetimibe16$477
Metoprolol Tartrate38$311
SotalolSotalol Hcl13$306
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$257
Isosorbide Mononitrate ErIsosorbide Mononitrate15$229
ClopidogrelClopidogrel Bisulfate13$225
Amlodipine Besylate38$223
Lisinopril17$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$61$65,35455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →